» Articles » PMID: 22894700

Longitudinal Fluctuations in PD1 and PD-L1 Expression in Association with Changes in Anti-viral Immune Response in Chronic Hepatitis B

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2012 Aug 17
PMID 22894700
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Controversy exists regarding the role of PD1 and its ligand PD-L1 in chronic hepatitis B infection. In some studies, persistent HBV infection has been attributed to high levels of PD-1 and PD-L1 expression on HBV-specific T-cells and antigen-presenting cells (APCs) respectively. Other studies revealed that the up-regulation of PD-1 and PD-L1 during an acute inflammation phase is required to offset increasing positive co-stimulatory signals to avoid severe damage by an over-vigorous immune response.

Methods: Fifteen chronic hepatitis B patients, with inflammatory flare episode, were recruited prospectively. Based on serum HBV-DNA, HBsAg load, and ALT values, inflammatory flare episode were divided into initial, climax, decline and regression phase. Blood sample and liver biopsy tissues from each individual were taken in these 4 phases respectively. Circulating and intra-hepatic PD1 and PD-L1 expression levels were monitored throughout the inflammatory flare episode by flow cytometry and immunostaining and these expression levels were related to the HBV-specific T-cell changes, expression of pro-inflammatory cytokines, HBV-DNA replication and HBV antigen load.

Results: ]The levels of PD-1 and PD-L1 expressions were significantly up-regulated in the inflammation ascending phase, initial and climax period and in parallel with HBV-specific colon expansion. It showed increasing the level of serum ALT and decreasing the HBV-DNA loads. As the level of inflammation reduced, the circulating and intra-hepatic PD1 and circulating PD-L1 decreased progressively in concordance with serum ALT, HBV-DNA and HBsAg loads decreased except intra-hepatic PD-1 expression. Intra-hepatic PD-L1 expression did not decrease significantly during the regression phase of inflammation compared to that in prior period. The intra-hepatic PD-L1 expression remained relatively on higher level when serum HBV-DNA load and ALT decreased to approximately normal range.

Conclusion: The relatively high level of intra-hepatic PD-L1 expression during the inflammatory regression period may contribute to constitute an immunosuppressive microenvironment, which facilitate persistent HBV infection via the inhibition of HBV-specific T cell clonal expansion.

Citing Articles

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.

Yoshimura A, Takeda T, Kataoka N, Tanimura K, Fukui M, Chihara Y Front Oncol. 2024; 14:1303543.

PMID: 38344209 PMC: 10853418. DOI: 10.3389/fonc.2024.1303543.


Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation.

Dumolard L, Aspord C, Marche P, Macek Jilkova Z Front Immunol. 2023; 14:1148111.

PMID: 37056774 PMC: 10086248. DOI: 10.3389/fimmu.2023.1148111.


Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.

Meng C, Sun S, Liang Y, Xu H, Zhang C, Zhang M Gut. 2022; 72(8):1544-1554.

PMID: 36316098 PMC: 10359590. DOI: 10.1136/gutjnl-2022-327059.


Pathogenicity and virulence of Hepatitis B virus.

Chuang Y, Tsai K, Ou J Virulence. 2022; 13(1):258-296.

PMID: 35100095 PMC: 8812780. DOI: 10.1080/21505594.2022.2028483.


Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study.

Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N Transl Lung Cancer Res. 2021; 10(8):3582-3593.

PMID: 34584858 PMC: 8435385. DOI: 10.21037/tlcr-21-461.


References
1.
Das A, Hoare M, Davies N, Lopes A, Dunn C, Kennedy P . Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 2008; 205(9):2111-24. PMC: 2526205. DOI: 10.1084/jem.20072076. View

2.
Muhlbauer M, Fleck M, Schutz C, Weiss T, Froh M, Blank C . PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol. 2006; 45(4):520-8. DOI: 10.1016/j.jhep.2006.05.007. View

3.
Rodig N, Ryan T, Allen J, Pang H, Grabie N, Chernova T . Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003; 33(11):3117-26. DOI: 10.1002/eji.200324270. View

4.
Matzinger P . Tolerance, danger, and the extended family. Annu Rev Immunol. 1994; 12:991-1045. DOI: 10.1146/annurev.iy.12.040194.005015. View

5.
Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G . PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006; 80(22):11398-403. PMC: 1642188. DOI: 10.1128/JVI.01177-06. View